Segmentation by type categorises the Chromatin Immunoprecipitation Sequencing market according to the methodological approach employed to capture protein‑DNA complexes. Antibody‑based ChIP, the dominant type, accounts for roughly 55 % of market revenue; it relies on highly specific antibodies to immunoprecipitate target histones or transcription factors, and its prevalence is driven by extensive reagent libraries and validated protocols. Tagged‑protein ChIP, representing about 20 %, uses epitope‑tagged constructs expressed in cells, offering higher specificity and reduced background at the cost of genetic manipulation. Native ChIP, which preserves chromatin without cross‑linking, contributes near 15 % and is preferred for studying histone variants and low‑affinity interactions. Emerging low‑input and single‑cell ChIP‑Seq methods, collectively forming 8 % of the market, address the need for profiling scarce clinical samples and heterogeneous cell populations. Finally, automated and high‑throughput platforms, comprising roughly 2 %, provide integrated liquid‑handling and sequencing pipelines that accelerate assay turnaround for large‑scale projects. Each type’s share reflects its maturity, cost structure, and alignment with specific research workflows, shaping the overall market composition and informing investment priorities.
